References
- 1
Valantine H.
Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment
of de novo malignancies after heart transplantation? Lessons learned from renal transplantation
and oncology.
J Heart Lung Transplant.
2007;
26
557-564
- 2
Kirklin J K, Naftel D C, Bourge R C, McGiffin D C, Hill J A, Rodeheffer R J, Jaski B E,
Hauptman P J, Weston M, White-Williams C.
Evolving trends in risk profiles and causes of death after heart transplantation:
a ten-year multi-institutional study.
J Thorac Cardiovasc Surg.
2003;
125
881-890
- 3
Taylor D O, Edwards L B, Boucek M M, Trulock E P, Aurora P, Christie J, Dobbels F,
Rahmel A O, Keck B M, Hertz M I.
Registry of the International Society for Heart and Lung Transplantation: twenty-fourth
official adult heart transplant report-2007.
J Heart Lung Transplant.
2007;
26
769-781
- 4 Lehmkuhl H, Dengler T, Hiemann N, Pethig K, Stempfle U, Wagner F. Working Group
“Thoracic Transplantation”/German Society for Cardiology .Malignancy in thoracic transplantation:
a German nationwide post-HTx malignancy registry. San Francisco, USA; International
Society for Heart and Lungtransplantation 2007
- 5
Potaris K, Radovancevic B, Thomas C D, Gregoric I, Vaporciyan A A, Riggs S A, Radovancevic R,
Vaughn W K, Frazier O H.
Lung cancer after heart transplantation: a 17-year experience.
Ann Thorac Surg.
2005;
79
980-983
- 6
Casadio F, Croci S, D'Errico Grigioni A, Corti B, Grigioni W F, Landuzzi L, Lollini P L.
Toward the definition of immunosuppressive regimens with antitumor activity.
Transplant Proc.
2005;
37
2144-2147
- 7
O'Neill J O, Edwards L B, Taylor D O.
Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation:
analysis of the transplant registry of the International Society for Heart and Lung
Transplantation.
J Heart Lung Transplant.
2006;
25
1186-1191
- 8
Ulrich C, Euvrard S, Salasche S, Schmook T.
Impact of new immunosuppressants on the dermatological outcome of organ transplant
patients.
J Am Acad Dermatol March.
2004;
50 (Suppl. 3)
P31
- 9
Opelz G, Döhler B.
Lymphomas after solid organ transplantation: a collaborative transplant study report.
Am J Transplant.
2004;
4
222-230
- 10
Ippoliti G, Rinaldi M, Pellegrini C, Viganò M.
Incidence of cancer after immunosuppressive treatment for heart transplantation.
Crit Rev Oncol Hematol.
2005;
56
101-113
- 11
Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl H B, Berger F, Hetzer R,
Reinke P.
Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative
disease in pediatric heart transplant patients.
J Heart Lung Transplant.
2008;
27
100-105
- 12
Trappe R U, Choquet S, Reinke P, Dreyling M, Mergenthaler H G, Jäger U, Kebelmann-Betzing C,
Jonas S, Lehmkuhl H, Anagnostopoulos I, Leblond V, Hetzer R, Dörken B, Riess H, Oertel S.
Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with
a second progression of PTLD after upfront chemotherapy: the role of single-agent
rituximab.
Transplantation.
2007;
84
1708-1712
- 13
Hauptman P J, Mehra M R.
It is time to stop ignoring malignancy in heart transplantation: a call to arms.
J Heart Lung Transplant.
2005;
24
1111-1113
Dr. med. Hans Brendan Lehmkuhl
DHZB
Augustenburger Platz 1
13353 Berlin
Germany
Telefon: + 49 (0) 30 45 93 20 00
Fax: + 49 (0) 30 45 93 21 00
eMail: lehmkuhl@dhzb.de
